21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile

Jagar Jasem ¹, Arya Amini ¹, Rachel Rabinovitch ¹, Virginia F Borges ¹, Anthony Elias ¹, Christine M Fisher ¹, Peter Kabos ²

Affiliations

¹ All authors: University of Colorado, Aurora, CO.
² All authors: University of Colorado, Aurora, CO peter.kabos@ucdenver.edu.

PMID: 27001563
35 References
25 citations

Abstract

Purpose: The 21-gene Recurrence Score (RS) assay is used to predict disease recurrence and benefit of chemotherapy in estrogen receptor-positive, lymph node-negative early-stage breast cancer (EBC). Our study is the first analysis of trends and differences in the use of the RS assay and its impact on recommending chemotherapy in a population-based data set.

Methods: Patients with EBC diagnosed from 2004 to 2012 and included in the National Cancer Data Base were analyzed. Multivariate logistic regression analysis was used to estimate the covariates associated with use of the test and its impact on chemotherapy decisions.

Results: The RS assay was ordered for 54.0% of the 143,032 identified patients. Of all the variables, RS assay had the strongest association with recommendation for chemotherapy, with an adjusted odds ratio (AOR) of 83 for high assay scores. When indicated, test use was significantly associated with younger age, white race, academic centers, private insurance, and pT2/pN0(i+) grade 2 to 3 disease. Black patients (AOR, 1.31; 95% CI, 1.20 to 1.43) and those treated in community facilities (AOR, 1.49; 95% CI, 1.35 to 1.63) were more likely to be tested outside the National Comprehensive Cancer Network guidelines. Black patients (AOR, 1.51; 95% CI, 1.31 to 1.69) and those with high tumor grade (AOR, 30.76; 95% CI, 26.48 to 35.73) had significantly higher assay scores. Younger black patients (AOR, 1.33; 95% CI, 1.16 to 1.54) were more likely to receive chemotherapy despite low assay scores.

Conclusion: The RS assay significantly influences clinicians' recommendations for chemotherapy in patients with EBC. Black patients tended to have higher assay scores, which may reflect use patterns or less favorable tumor biology for estrogen receptor-positive disease. There are significant differences in use and clinical implications of the test on the basis of race, insurance, and type of facility.

Other Links

Free PMC article
Full text on Journal of clinical oncology : official journal of the American Society of Clinical Oncology

References
Cited By

References
Missed opportunities: racial disparities in adjuvant breast cancer treatment. Nina A Bickell, Jason J Wang, +5 authors, Amber A Guth. less J Clin Oncol, 2006 Mar 22; 24(9). PMID: 16549830 Highly Cited.
The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Foluso O Ademuyiwa, Austin Miller, +5 authors, Sunil Badve. less Breast Cancer Res Treat, 2011 Jan 05; 126(3). PMID: 21197567
Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Soonmyung Paik. Oncologist, 2007 Jul 03; 12(6). PMID: 17602054
Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing. Megan C Roberts, Morris Weinberger, +5 authors, Stephanie B Wheeler. less Breast Cancer Res Treat, 2015 Jul 29; 153(1). PMID: 26216535 Free PMC article.
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Gong Tang, Steven Shak, +6 authors, Norman Wolmark. less Breast Cancer Res Treat, 2011 Jan 12; 127(1). PMID: 21221771 Free PMC article.
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. John Hornberger, Leon E Cosler, Gary H Lyman. Am J Manag Care, 2005 May 19; 11(5). PMID: 15898220
Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Juhi Asad, Allyson F Jacobson, +7 authors, Paul I Tartter. less Am J Surg, 2008 Sep 24; 196(4). PMID: 18809056
The influence of a gene expression profile on breast cancer decisions. Leonard R Henry, Alexander Stojadinovic, +3 authors, Peter W Soballe. less J Surg Oncol, 2009 Feb 11; 99(6). PMID: 19204954
The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer. Richard H de Boer, Caroline Baker, +3 authors, G Bruce Mann. less Med J Aust, 2013 Aug 06; 199(3). PMID: 23909545
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. Shelly S Lo, Patricia B Mumby, +8 authors, Kathy S Albain. less J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065191 Highly Cited.
Socioeconomic disparities in health: pathways and policies. Nancy E Adler, Katherine Newman. Health Aff (Millwood), 2002 Mar 20; 21(2). PMID: 11900187 Highly Cited. Review.
US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer. John Hornberger, Rebecca Chien, Katie Krebs, Louis Hochheiser. J Oncol Pract, 2011 Sep 03; 7(3 Suppl). PMID: 21886510 Free PMC article.
Prospective study of the effect of the 21-gene assay on adjuvant clinical decision-making in Japanese women with estrogen receptor-positive, node-negative, and node-positive breast cancer. Hideko Yamauchi, Chizuko Nakagawa, +7 authors, Seigo Nakamura. less Clin Breast Cancer, 2013 Dec 11; 14(3). PMID: 24321102
21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome. Mary Jo Lund, Marina Mosunjac, +7 authors, Ruth M O'Regan. less Cancer, 2011 Jul 02; 118(3). PMID: 21720988
Development of the 21-gene assay and its application in clinical practice and clinical trials. Joseph A Sparano, Soonmyung Paik. J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258979 Highly Cited. Review.
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. J Albanell, A González, +17 authors, A Lluch. less Ann Oncol, 2011 Jun 10; 23(3). PMID: 21652577
Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. Michaela A Dinan, Xiaojuan Mi, +2 authors, Shelby D Reed, Gary H Lyman, Lesley H Curtis. less JAMA Oncol, 2015 Aug 28; 1(8). PMID: 26313372
Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. Idan Menashe, William F Anderson, Ismail Jatoi, Philip S Rosenberg. J Natl Cancer Inst, 2009 Jul 09; 101(14). PMID: 19584327 Free PMC article.
Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. Roman Rouzier, Paolo Pronzato, +3 authors, William J Valentine. less Breast Cancer Res Treat, 2013 Jun 01; 139(3). PMID: 23722312 Free PMC article. Systematic Review.
The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy. D B Geffen, S Abu-Ghanem, +6 authors, M Koretz. less Ann Oncol, 2011 Mar 03; 22(11). PMID: 21363879
Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. Dawn L Hershman, Joseph M Unger, +5 authors, Kathy S Albain. less J Clin Oncol, 2009 Mar 25; 27(13). PMID: 19307504 Free PMC article.
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. R C Bast, P Ravdin, +8 authors, American Society of Clinical Oncology Tumor Markers Expert Panel. less J Clin Oncol, 2001 Mar 17; 19(6). PMID: 11251019 Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark. less N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335 Highly Cited.
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. W Eiermann, M Rezai, +13 authors, J Blohmer. less Ann Oncol, 2012 Nov 09; 24(3). PMID: 23136233 Free PMC article.
The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. Josh J Carlson, Joshua A Roth. Breast Cancer Res Treat, 2013 Aug 27; 141(1). PMID: 23974828 Free PMC article. Highly Cited. Systematic Review.
Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. Hannah K Weir, Michael J Thun, +7 authors, Brenda K Edwards. less J Natl Cancer Inst, 2003 Sep 04; 95(17). PMID: 12953083 Highly Cited. Review.
Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. Ruth Oratz, Dev Paul, Allen L Cohn, Scot M Sedlacek. J Oncol Pract, 2007 Jul 01; 3(4). PMID: 20859407 Free PMC article.
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Shelby D Reed, Michaela A Dinan, Kevin A Schulman, Gary H Lyman. Genet Med, 2012 Sep 15; 15(3). PMID: 22975761 Free PMC article.
Comparison of cases captured in the national cancer data base with those in population-based central cancer registries. Catherine C Lerro, Anthony S Robbins, Jerri Linn Phillips, Andrew K Stewart. Ann Surg Oncol, 2013 Mar 12; 20(6). PMID: 23475400
Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. Aron Goldhirsch, William C Wood, +3 authors, Hans-Jörg Senn. less J Clin Oncol, 2003 Jul 09; 21(17). PMID: 12847142 Highly Cited. Review.
Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer. Clara Chen, Rahul Dhanda, +2 authors, Wan-Yu Tseng, Michael Forsyth, Debra A Patt. less J Oncol Pract, 2013 Aug 15; 9(4). PMID: 23942918 Free PMC article.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America. less Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174 Free PMC article. Highly Cited.
Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Ayal A Aizer, Tyler J Wilhite, +7 authors, Paul L Nguyen. less Cancer, 2014 May 28; 120(10). PMID: 24863392 Highly Cited.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge. less N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349 Free PMC article. Highly Cited.
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. P Eifel, J A Axelson, +11 authors, D Roter. less J Natl Cancer Inst, 2001 Jul 05; 93(13). PMID: 11438563 Highly Cited. Review.

Citedby
Scientific Achievements May Not Reach Everyone: Understanding Disparities in Acute Leukemia. Manali I Patel. Curr Hematol Malig Rep, 2016 May 23; 11(4). PMID: 27209407 Review.
Breast cancer: The 21-gene recurrence score - biology remains at the forefront. Shannon L Puhalla, Nancy E Davidson. Nat Rev Clin Oncol, 2016 Jun 15; 13(8). PMID: 27296295
21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013. Benjamin M Parsons, Jeffrey Landercasper, +3 authors, Leah L Dietrich. less Breast Cancer Res Treat, 2016 Aug 11; 159(2). PMID: 27507245 Free PMC article.
The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients. Yun Li, Allison W Kurian, +6 authors, Timothy P Hofer. less Breast Cancer Res Treat, 2016 Dec 25; 161(3). PMID: 28012085 Free PMC article.
Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. Carlos H Barcenas, Akshara Raghavendra, +10 authors, Debu Tripathy. less Cancer, 2017 Feb 16; 123(13). PMID: 28199747 Free PMC article.
Oncologist and organizational factors associated with variation in breast cancer multigene testing. Tracy A Lieu, G Thomas Ray, +8 authors, Jeanne S Mandelblatt. less Breast Cancer Res Treat, 2017 Feb 23; 163(1). PMID: 28224383 Free PMC article.
Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer. Terri P McVeigh, Michael J Kerin. Breast Cancer (Dove Med Press), 2017 Jun 16; 9. PMID: 28615971 Free PMC article. Review.
Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. Melissa A Troester, Xuezheng Sun, +16 authors, Charles M Perou. less J Natl Cancer Inst, 2017 Sep 02; 110(2). PMID: 28859290 Free PMC article.
Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study. Prema P Peethambaram, Tanya L Hoskin, +3 authors, Judy C Boughey. less NPJ Breast Cancer, 2017 Oct 27; 3. PMID: 29067357 Free PMC article.
Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults. Talha Shaikh, Elizabeth A Handorf, +2 authors, Joshua E Meyer, Michael J Hall, Nestor F Esnaola. less JAMA Oncol, 2017 Nov 10; 4(2). PMID: 29121143 Free PMC article.
Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals. Purificación Martínez Del Prado, Isabel Alvarez-López, +7 authors, Javier Mar. less Clinicoecon Outcomes Res, 2018 Mar 30; 10. PMID: 29593426 Free PMC article.
The Art of War and oncology: applying the principles of strategy and tactics to greater effect in the era of targeted therapy. Emil Lou. Ann Transl Med, 2018 Jun 19; 6(9). PMID: 29911116 Free PMC article.
Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology. Danielle M Bello, Christy Russell, +2 authors, Debbie McCullough, Marni Tierno, Monica Morrow. less Ann Surg Oncol, 2018 Jul 04; 25(10). PMID: 29968028 Free PMC article.
Breast Cancers of Special Histologic Subtypes Are Biologically Diverse. Audree B Tadros, Hannah Y Wen, Monica Morrow. Ann Surg Oncol, 2018 Aug 11; 25(11). PMID: 30094484 Free PMC article.
Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia. Lindsay J Collin, Ming Yan, +8 authors, Lauren E McCullough. less NPJ Breast Cancer, 2019 Oct 05; 5. PMID: 31583272 Free PMC article.
Blending Insights from Implementation Science and the Social Sciences to Mitigate Inequities in Screening for Hereditary Cancer Syndromes. Laura Senier, Colleen M McBride, +2 authors, Alex T Ramsey, Vence L Bonham, David A Chambers. less Int J Environ Res Public Health, 2019 Oct 18; 16(20). PMID: 31618814 Free PMC article.
Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30. Seho Park, Yunan Han, +7 authors, Yikyung Park. less Breast Cancer Res, 2019 Oct 18; 21(1). PMID: 31619259 Free PMC article.
MAGI1, a New Potential Tumor Suppressor Gene in Estrogen Receptor Positive Breast Cancer. Begoña Alday-Parejo, François Richard, +5 authors, Curzio Rüegg. less Cancers (Basel), 2020 Jan 23; 12(1). PMID: 31963297 Free PMC article.
Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy? Abiola F Ibraheem, David J Press, Olufunmilayo I Olopade, Dezheng Huo. Cancer, 2018 Nov 06; 125(2). PMID: 30387876 Free PMC article.
Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ. Ying Liu, Robert West, Jason D Weber, Graham A Colditz. Cancer, 2019 May 24; 125(18). PMID: 31120565 Free PMC article.
Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients? Jing Yu, Jiayi Wu, +6 authors, Kunwei Shen. less Front Oncol, 2020 Jun 02; 10. PMID: 32477946 Free PMC article.
Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30. Jing Yu, Jiayi Wu, +6 authors, Kunwei Shen. less Oncol Lett, 2020 Jul 30; 20(2). PMID: 32724396 Free PMC article.
Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016. Thomas M Schwedhelm, Judy R Rees, +4 authors, Erika L Moen. less BMC Cancer, 2020 Sep 05; 20(1). PMID: 32883270 Free PMC article.
Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer. Yunan Han, Zhi-Feng Miao, +3 authors, Ying Liu. less Breast Cancer Res Treat, 2020 Sep 16; 184(3). PMID: 32929567 Free PMC article.
Hypoxia gene expression signatures as predictive biomarkers for personalising radiotherapy. Lingjian Yang, Catharine Ml West. Br J Radiol, 2018 Mar 08; 92(1093). PMID: 29513038 Free PMC article. Review.

BioKDE: Biomedical Knowledge Discovery Engine

Abstract

Other Links